23 Jan 2007 07:00
For immediate release 23 January 2007 LiDCO Group Plc ('LiDCO' or 'the Company')
Publication of successful USA based study using LiDCO's technology to monitor hemodynamics in children
LiDCO, the UK based, AIM - quoted cardiovascular monitoring company, announces the publication by a specialist medical journal of a study conducted by the Department of Pediatrics at Baylor College of Medicine, Texas. The study investigated the accuracy of the LiDCO arterial waveform power approach (PulseCOtm software) to continuously measure cardiac output in children undergoing cardiac catherization. This technique had not been previously validated in pediatric patients.
The study, published in Pediatric Critical Care Medicine 2006 (Volume 7: Issue 6, pages 532-535) stated that: "Arterial pulse wave analysis by the PulseCO System provides a novel, minimally invasive method of determining real-time cardiac output in children."
Dr Jeffrey Kim, Baylor College, section of pediatric cardiology stated that:
"Early detection of low cardiac output states and the subsequent rapid institution of therapy, has been shown to improve outcomes in critically ill children. Unfortunately, our ability to clinically assess the adequacy of cardiac output in sick children has remained poor. Standard methods of determining cardiac output remain risky and problematic, and this is only amplified in the smallest of patients. Arterial pulse wave analysis, utilizing the PulseCO system, provides a minimally invasive method of accurately and safely measuring real time cardiac output in children. This should allow for the development of goal directed therapy in critically ill children, which has the ultimate potential of improving morbidity and mortality."
Dr Terry O'Brien, CEO LiDCO Group Plc commented; "These study demonstrate a new and until now unreported, clinical application for our technology. We are excited about the possibility that our technology can also be used to help in the advancement of care and in particular to allow goal directed therapy in children."
- ENDS -
Note re Pediatric Use of the LiDCO technology
In licensed territories such as the USA the LiDCO System is already approved for monitoring of hemodynamics in both adults and children above 40 kg's in weight.
For more information please contact:
LiDCO Group Plc Tel: +44 (0)20 7749 1500 Terry O'Brien - Chief Executive
Buchanan Communications Tel: +44 (0)20 7466 5000 Tim Anderson, James Strong Notes for Readers/EditorsAbout LiDCO Group Plc
LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London.
The Company's manufacturing facility is in Hoxton, London, UK and its current
products are:
* LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;
* LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.
Distribution Network:
The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of specialty critical care distributors.
LIDCO GROUP PLC